In Vitro Characterization of the Effects of MCI-154, a Novel Cardiotonic Agent, on Cardiac Tissues

Akihiro NARIMATSU, Yoshimi KITADA*, Naoya SATOH, Miyuki MORITA, Akiko MUROYAMA1, Masaki KOBAYASHI1 and Yasushi OHIZUMI1

Pharmaceuticals Laboratory, Research Center, Mitsubishi Kasei Corporation, 1000 Kamoshida-cho, Midori-ku, Yokohama 227, Japan
1Mitsubishi-Kasei Institute of Life Sciences, 11 Minamiooya, Machida, Tokyo 194, Japan

Accepted December 9, 1988

Abstract—In vitro cardiac effects of a cardiotonic drug, MCI-154, for which the main action mechanism was proposed to be the enhancement of Ca²⁺ sensitivity of cardiac contractile proteins, were investigated. MCI-154 (3×10⁻⁸–3×10⁻⁴ M) increased the developed tension in isolated ventricular muscles from cats, dogs, guinea pigs and rats and increased that of isolated left atrial muscles of guinea pigs and rats. However, species differences were observed in the responses to MCI-154. The positive inotropic potency of MCI-154 was stronger than those of amrinone and milrinone. In the isolated right atria from guinea pigs and rats, properties of the chronotropic effect of MCI-154 were different from those of amrinone and milrinone. The positive inotropic action of MCI-154 was not affected by phentolamine, propranolol, cimetidine and tetrodotoxin. MCI-154 did not inhibit cardiac Na⁺,K⁺-ATPase. MCI-154 modelately stimulated Ca²⁺-uptake of isolated cardiac sarcoplasmic reticulum (SR), but induced no release of Ca. ²⁺ from the SR. These results support the view that the main mechanism for the action of MCI-154 is the enhancement of Ca²⁺ sensitivity of cardiac contractile proteins.

MCI-154, 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride is a novel cardiotonic agent (1-4) with a vasodilator property (2-7). We and Satoh et al. have shown that MCI-154 improved cardiac performance in animal heart failure models (4, 8). Direct positive inotropic effects of MCI-154 on isolated cardiac muscles were demonstrated in ventricular muscles of dogs (9) and guinea pigs (10). However, inotropic effects of the agent on the ventricular muscles of other animals species and chronotropic effects on spontaneously beating right atria have not been examined. Such examinations are important to compare the pharmacological profile of MCI-154 with those of new cardiotonic agents such as amrinone and milrinone, since species difference in the inotropic response and the direct positive chronotropic response to these agents have been reported (11-13).

Concerning the mechanisms responsible for the cardiotonic action of MCI-154, we have reported that 1) MCI-154 increased the Ca²⁺ sensitivity of the contractile protein system in the skinned cardiac muscle of the guinea pig (14, 15), 2) MCI-154 exerted little effect on the crude phosphodiesterase of the canine heart (9), and 3) MCI-154 did not increase significantly cyclic AMP content in the dog heart (9). These results suggest that the Ca²⁺-sensitivity increasing effect may be the main mechanism for the positive inotropic action of MCI-154. To clarify this, we have to examine other possible mechanisms because myocardial contraction is regulated by various mechanisms and many interventions can be theoretically cardiotonic (16, 17).

In the present study, we investigated the
effects of MCI-154 on isolated ventricular and atrial muscles from various animal species and examined some possible mechanisms for the action of MCI-154 other than the enhancement of Ca²⁺ sensitivity of cardiac contractile proteins.

Materials and Methods

Isolated heart muscle preparations: Male Hartley guinea pigs (250–400 g), male Wistar rats (350–400 g), male Japanese white rabbits (2–3 kg), dogs (6–14 kg) and cats (2.5–4 kg) of either sex were used. The hearts were isolated from these animals. The right ventricular papillary muscles were dissected from the guinea pig, rat, rabbit and cat hearts. The right ventricular trabeculae were excised from the dog heart. The right and left atria were dissected from the rat and guinea pig hearts. These muscles were mounted in organ baths containing modified Krebs-Ringer solution at 32°C (the ventricular muscles) or 37°C (the atrial muscles) and bubbled with 95% O₂ and 5% CO₂. The solution had the following composition: 120.3 mM NaCl, 4.8 mM KCl, 1.8 mM CaCl₂, 1.3 mM MgSO₄, 1.2 mM KH₂PO₄, 1.2 mM NaHCO₃ and 5.5 mM glucose. The guinea pig, rat, cat and dog ventricular muscles and the guinea pig atria were stretched with a resting tension of 0.5 g and the rabbit papillary muscles, with 0.8 g. The ventricular muscles and left atria were stimulated at 1 and 2 Hz, respectively, with rectangular pulses of 1.2×threshold voltage and 1 msec duration. Contractile force of the cardiac muscles was measured by a force-displacement transducer (Nihon Kohden, TB-612T and Minebea Co. Ltd., UL-2GR) and recorded on a rectilinear recorder (NEC Sansei, 8K-23). Spontaneously beating rate of the right atria was counted with a cardiotachometer triggered by pulses of the contraction and recorded on a rectilinear recorder. After 60 min equilibration time, drugs were cumulatively added into the organ baths. When the influence of various blockers on the action of MCI-154 was examined, the inotropic effect of MCI-154 was expressed as the percentage fraction of the maximum effect induced by isoproterenol in the same preparation in order to eliminate the interindividual variability in the response to MCI-154.

Na⁺,K⁺-ATPase assay: Na⁺,K⁺-ATPase was prepared from the guinea pig myocardium by the method of Pitts and Schwartz (18). After 5 min pretreatment with the enzyme, reaction was carried out at 37°C for 15 min in 0.5 ml of a reaction mixture that contained 100 mM NaCl, 20 mM KCl, 5 mM MgCl₂, 3 mM ATP and 50 mM Tris-HCl (pH 7.4). The reaction procedure was the same as described by Ohizumi and Yasumoto (19).

Ca²⁺-pumping and Ca²⁺-releasing activities of fragmented sarcoplasmic reticulum (SR) of the heart muscle: Cardiac SR was isolated from the dog heart by the method of Harigaya and Schwartz (20). Ca²⁺-pumping activity of the SR was measured according to the method of Nakamura et al. (21) and Kobayashi et al. (22). Briefly, the SR (1.5 mg/ml) was suspended in an assay mixture (final volume, 1 ml) containing 0.05 mM CaCl₂, 90 mM KCl, 3 mM MgCl₂, 2 mM NaN₃, 5 mM creatine phosphate and 50 mM Mops-KOH buffer (pH 7.0) at 30°C. Ca²⁺ concentration in the mixture was monitored with a Ca²⁺ electrode (21, 22). The reaction of Ca²⁺ uptake was started by adding ATP and creatine kinase (final concentrations were 1 mM and 0.1 mg/ml, respectively). Ca²⁺-releasing action of the drugs was examined by adding the drugs to the reaction mixture when the Ca²⁺ concentration of the mixture was reduced to submicromolar level.

SR Ca²⁺-ATPase assay: According to the method of Kobayashi et al. (22), SR Ca²⁺-ATPase was prepared from the dog heart muscle and the enzyme activity was measured.

Drugs: MCI-154, amrinone and milrinone were synthesized at our Research Center. Other drugs used were as follows: phentolamine mesylate (Regitin®, Ciba-Geigy), propranolol hydrochloride (Sigma), cimetidine (Fujisawa Pharmaceutical Co.), tetrodotoxin (Sankyo Pharmaceutical Co.), ouabain (Tokyo Kasei) and caffeine (Wako Pure Chemical).

MCI-154, propranolol, tetrodotoxin, ouabain and caffeine were dissolved in 0.9% NaCl solution. Cimetidine was dissolved in 0.1 N HCl. Amrinone and milrinone were dissolved in 0.05 N lactic acid and 0.05 N HCl, respectively. Phentolamine was supplied in
ampoules. These drug solutions were diluted with 0.9% NaCl solution when necessary.

Statistical analysis: The results are expressed as means±S.E.M. The statistical analysis of effects of MCI-154 was carried out using Student's t-test. Two-way analysis of variance was used to determine the significance of difference between blocker-treated and non-treated groups. A value of P<0.05 was considered to indicate significance.

Results

Effects of MCI-154 on developed tension of isolated ventricular muscles from various animal species and isolated left atria guinea pigs and rats: MCI-154 (3×10⁻⁸–3×10⁻⁴ M) increased developed tension of cat, dog, guinea pig and rabbit ventricular muscles in a concentration-dependent manner (Fig. 1A). However, there was some species difference in the positive inotropic effects of MCI-154 as indicated by EC50% (concentration for increasing developed tension by 50%). The approximate EC50% values in cat, dog, guinea pig and rabbit ventricular muscles were 11, 0.44, 0.95 and 2.1 μM, respectively. Although MCI-154 also increased significantly the developed tension of rat papillary muscle, the sensitivity of the rat muscles to MCI-154 was much less than those of other species, and the increase in developed tension of the rat ventricular muscle did not reach 50% even at the highest concentration (3×10⁻⁴ M).

On the left atria of guinea pigs and rats, MCI-154 also exerted a concentration-dependent positive inotropic effect (Fig. 1B). At 3×10⁻⁴ M the increase in developed tension of the rat left atria (80.6%) was more than that of the rat papillary muscles (19.7%, Fig. 1A). Nevertheless, the sensitivity of the rat atria to MCI-154 was much less than that of guinea pig atria (Fig. 1B).

Comparison of inotropic and chronotropic effects of MCI-154 on isolated cardiac tissues from guinea pigs and rats with those of amrinone and milrinone: In the guinea pig papillary muscle preparations, MCI-154 (3×10⁻⁸–3×10⁻⁴ M), amrinone (3×10⁻⁸–10⁻⁴ M) and milrinone (10⁻⁷–3×10⁻⁴ M) increased developed tension in a concentration-dependent manner (Fig. 2A). Approximate EC50% of MCI-154, amrinone and milrinone were 0.95, 558 and 6.6 μM, respectively. MCI-154 was about 590 and 7 times as potent as amrinone and milrinone, respectively. In the rat papillary muscle preparations, MCI-154 (above 10⁻⁴ M) produced the increase in developed tension as mentioned above (Figs. 1A and 3A). However, milrinone up to 3×10⁻⁴ M did not increase developed tension in these preparations, and even decreased it at higher concentrations (Fig. 3A).

Chronotropic effects of MCI-154, amrinone and milrinone on spontaneously beating right
Atria of guinea pigs are shown in Fig. 2B. Amrinone (10^{-5}-10^{-3} M) and milrinone (10^{-7}-10^{-4} M) increased beating rate in a concentration-related manner. In contrast with this, the concentration-response curve of MCI-154 was bell-shaped; i.e., MCI-154 caused a modelate increase in atrial rate in the concentration range of 10^{-7} - 3 \times 10^{-5} M, but caused a decrease in the rate at higher concentrations (10^{-4} - 3 \times 10^{-4} M) (Fig. 2B). In the right atrium preparations of rats, MCI-154 produced only little or no increase in the beating rate up to 10^{-4} M and produced a moderate increase at 3 \times 10^{-4} M (Fig. 3B). In contrast with MCI-154, milrinone (above 3 \times 10^{-8} M) increased the beating rate in a concentration-dependent manner (Fig. 3B).

Effects of receptor or channel blockers on the positive inotropic response of isolated guinea pig papillary muscles to MCI-154: Phentolamine (10^{-6} M), propranolol (10^{-6} M), cimetidine (10^{-5} M) and tetrodotoxin (10^{-5} M) did not significantly modify the positive inotropic effect of MCI-154 (Fig. 4).

Effect on cardiac Na^+,K^+-ATPase: MCI-154 in the concentration range of 10^{-6} to
10^-4 M exerted almost no effect on the cardiac Na^+,K^+-ATPase of the guinea pig (Table 1). Ouabain (10^-4 M) completely inhibited this enzyme (Table 1).

**Effects of MCI-154 on pumping and releasing of Ca^{2+} by fragmented SR of the canine myocardium:** The Ca^{2+}-pumping activity of fragmented SR could be observed by directly measuring extravesicular Ca^{2+} concentration with a Ca^{2+} electrode (Fig. 5). Immediately after the addition of ATP, free Ca^{2+} concentration decreased rapidly due to the formation of Ca^{2+}-ATP complexes and further decreased gradually due to the active Ca^{2+} uptake by the fragmented myocardial SR. The profile of net Ca^{2+} uptake exhibited a biphasic time course (slow and fast phases). The slow-uptake phase continued 2–3 min and was followed by the fast-uptake phase. Ca^{2+} uptake became slower when fragmented SR had been filled with Ca^{2+} and the extravesicular Ca^{2+} concentration was reduced to submicromolar levels. Using this system, the effects of MCI-154 was examined on Ca^{2+}-pumping and releasing by SR. Pretreatment of MCI-154 (10^-7–10^-6 M) accelerated Ca^{2+} uptake in a concentration-related manner (Fig. 5). For investigating the Ca^{2+} releasing effect, MCI-154 (3×10^-5–6×10^-5 M) was administered when fragmented SR was filled with Ca^{2+} (Fig. 6A). No increase in extravesicular Ca^{2+} concentration was observed, indicating that MCI-154 did not release Ca^{2+} from the SR. On the other hand, caffeine at the concentration of 1 mM released Ca^{2+} from the SR (Fig. 6B).

**Effect on cardiac SR Ca^{2+}-ATPase:** MCI-154 (10^-7–10^-6 M) moderately but sig-

---

**Table 1.** Effects of MCI-154 and ouabain on Na^+,K^+-ATPase of the guinea pig myocardium

| Drug       | Conc. (M) | % change in activity |
|------------|-----------|----------------------|
| MCI-154    | 10^-6     | -3.8                 |
|            | 10^-5     | -1.4                 |
|            | 10^-4     | -2.7                 |
| Ouabain    | 10^-4     | -100                 |

Each value represents the mean of two determinations.
Significantly increased the SR Ca\textsuperscript{2+}-ATPase activity (Table 2). However at a higher concentration (10\textsuperscript{-5} M), no significant increase in the ATPase activity was observed (Table 2).

**Discussion**

MCI-154 increased developed tension in ventricular muscles isolated from cats, dogs, guinea pigs, rabbits and rats. These results indicate that MCI-154 exerts a direct positive inotropic effect on the myocardium. However, sensitivity to MCI-154 was somewhat different among the animal species. Such species difference in inotropic sensitivity was also observed for milrinone in the present study and has also been reported for other cardio tonic drugs such as amrinone and OPC-8212 (13). Especially, the sensitivity to milrinone of rat ventricular muscles was very low, and no increase in developed tension was observed in the present experiment. On the contrary, MCI-154 significantly increased the developed tension of rat ventricular and atrial muscles even though the sensitivity of the rat cardiac muscles to MCI-154 was lower than that of other animal species. In this respect, MCI-154 is different from amrinone, milrinone and OPC-8212.

In the comparative study, it was revealed that the positive inotropic potency of MCI-
154 in guinea pig papillary muscle preparations was higher than those of typical non-catecholamine, non-cardiac glycoside cardiotonic drugs, amrinone and milrinone. The order of the potencies of these drugs was the same as that obtained after i.v. injection in anesthetized dogs (4).

In the right atrial preparations, a relevant contrast was observed between the chronotropic effect of MCI-154 and those of amrinone and milrinone. The concentration-response of the guinea pig atria to MCI-154 was biphasic, a slight increase in beating rate at lower concentrations and a decrease at higher ones. On the other hand, only a concentration-dependent increase in the rate was produced by amrinone and milrinone. In the right atrium preparations of the rat, MCI-154 (up to $10^{-4}$ M) produced only a small increase in beating rate. However, MCI-154 at $3 \times 10^{-4}$ M increased the rate, which contrasts with the results in the guinea pig preparations that showed a negative chronotropic response to this drug. The mechanism by which such a difference in the responses of the both species to the high doses of MCI-154 was caused remains unknown presently. In contrast with MCI-154, milrinone increased dose-dependently the rat atrial rate. These chronotropic properties of MCI-154 may be beneficial in the treatment of heart failure. In whole animal experiments, it has been shown that MCI-154 caused a relatively small increase in heart rate in comparison with its potent positive inotropic effect (4).

As cardiac contraction is regulated by various mechanisms, one can increase cardiac contractility by the intervention of some of the mechanisms (16, 17). Stimulations of adrenergic alpha, beta and histamine 2 receptors and of sodium channels cause an increase in cardiac contractility. The present results obtained by using the blockers at appropriate concentrations (13, 23) ruled out such possibilities for MCI-154. MCI-154 did not inhibit Na⁺,K⁺-ATPase, indicating that the cardiac glycoside-like mechanism can be excluded.

SR can be a site of action of positive inotropic agents. For example, caffeine increases cardiac contraction by releasing Ca²⁺ from SR (24); and gingerol, a recently found cardiotonic agent, exerts its action by a mechanism involving direct stimulation of the Ca²⁺ pumping activity of SR (22, 25). Therefore, we investigated the effects of MCI-154 on Ca²⁺ pumping activity of the isolated SR and on Ca²⁺ release from the SR. MCI-154 somewhat stimulated the Ca²⁺ pumping activity, which is probably due to the enhancement of SR Ca²⁺-ATPase activity as demonstrated in the present experiment. MCI-154 did not induce Ca²⁺ release from SR, indicating that this agent has no caffeine-like action. These results are consistent with those obtained in cardiac skinned fibers of the guinea pig (15). Thus the stimulatory effect of MCI-154 on SR Ca²⁺ uptake may be involved in the cardiotonic action of MCI-154. However, as the effect was relatively weak, it would not be the primary mechanism for the positive inotropic effect of the agent. The effect also provides an explanation for why relaxation time of contraction was not prolonged by MCI-154 in spite of its increasing effect on the Ca²⁺ sensitivity of contractile proteins (14, 15). Compared with an agent like pimobendan, which is reported to increase the Ca²⁺ sensitivity and prolong relaxation time (23), no impairment of the relaxation by MCI-154 would be advantageous because not only contraction but also relaxation of the heart is impaired in patients with heart failure (26, 27).

We have already reported that MCI-154 inhibited less weakly the crude phos-
phodiesterase of the canine heart than cyclic AMP phosphodiesterase inhibitors, amrinone and milrinone, and that MCI-154 did not increase significantly cyclic AMP content in the dog myocardium, suggesting little involvement of the cyclic AMP mechanism (9). We have also demonstrated that MCI-154 increased the Ca2+ sensitivity of the contractile protein system in the skinned cardiac muscle of the guinea pig (14, 15). These results together with those in the present study support the view that the main mechanism for the cardiotonic action of MCI-154 is the enhancement of the Ca2+ sensitivity of the cardiac contractile proteins (14, 15).

In conclusion, the present study demonstrated the direct positive inotropic effect of MCI-154 on the isolated ventricular muscles from various animal species. The inotropic and chronotropic effects of MCI-154 were different from those of amrinone and milrinone in the potency and mode of action. MCI-154 stimulated Ca2+ uptake by cardiac SR, although the effect may not be the main action mechanism of MCI-154. These properties of MCI-154 differentiate this agent from other new cardiotonic drugs such as amrinone, milrinone and pimobendan.

Acknowledgment: We thank Mrs. Reiko Tsurui for her excellent technical assistance.

References
1 Okushima, H., Narimatsu, A., Kobayashi, M., Furuya, R., Tsuda, K. and Kitada, Y.: A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)-phenyl]pyridazinones and related derivatives. J. Med. Chem. 30, 1157-1161 (1987)
2 Narimatsu, A., Kitada, Y., Satoh, N., Suzuki, R., Kobayashi, M. and Okushima, H.: Cardiovascular profile of MCI-154, a novel and potent cardiotonic agent with vasodilator effect. Japan. J. Pharmacol. 40, Supp. 234P (1986)
3 Narimatsu, A., Kitada, Y., Satoh, N., Suzuki, R., Kobayashi, M. and Okushima, H.: Cardiovascular pharmacology of MCI-154, a novel and potent cardiotonic compound with vasodilator property: Comparison with other cardiotonics. Fed. Proc. 45, 810 (1986)
4 Narimatsu, A., Kitada, Y., Satoh, N., Suzuki, R. and Okushima, H.: Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties. Arzneimittelforschung 37, 398-406 (1987)
5 Shimshak, T., Gross, G.J., Brooks, H.L. and Warltier, D.C.: Systemic and coronary hemodynamic effects of 4 cardiotonic agents in conscious, instrumented dogs. Fed. Proc. 45, 811 (1986)
6 Hosono, M. and Taira, N.: Cardiac and coronary vasodilator effects of the novel cardiotonic agent, MCI-154, assessed in isolated, blood-perfused dog heart preparations. J. Cardiovasc. Pharmacol. 10, 692-698 (1987)
7 Shibata, S., Satake, N., Hester, R.K., Kurahashi, K. and Ito, M.: The mode of vasoconstrictor action of a pyridazine derivative (MCI-154), a new cardiotonic agent, on contractile responses induced by α-adrenoceptor agonists and 45Ca influx in isolated vascular smooth muscles. Eur. J. Pharmacol. 145, 113-121 (1988)
8 Satoh, K., Nunoki, K., Goto, T., Hosono, M., Hashimoto, H., Sato, Y. and Taira, N.: Improvement of pentobarbital-induced heart failure by MCI-154, a novel and potent cardiotonic agent, in the dog heart-lung preparation. J. Pharmacol. Exp. Ther. 243, 639-645 (1987)
9 Kitada, Y., Narimatsu, A., Suzuki, R., Endo, M. and Taira, N.: Does the positive inotropic action of a novel cardiotonic agent, MCI-154 involve mechanisms other than cyclic AMP? J. Pharmacol. Exp. Ther. 243, 639-645 (1987)
10 Katayama, S., Narimatsu, A., Suzuki, R., Iijima, T. and Taira, N.: Changes in membrane potentials and currents of ventricular cells of the guinea pig heart by a new cardiotonic drug, MCI-154. Japan. J. Pharmacol. 44, 481-488 (1987)
11 Alousi, A.A., Farah, A.E., Lesher, G.Y. and Opalka, C.J., Jr.: Cardiotoxic activity of amrinone-Win 40680 [5-amino-3,4'-bipyridin-6(1H)-one]. Circ. Res. 45, 666-677 (1979)
12 Alousi, A.A., Stankus, G.P., Stuart, J.C. and Walton, L.H.: Characterization of the cardiotonic effects of milrinone, a new and potent cardiotonic bipyridine, on isolated tissues from several animal species. J. Cardiovasc. Pharmacol. 5, 804-811 (1983)
13 Yamashita, S., Hosokawa, T., Kojima, M., Mori, T. and Yabuuchi, Y.: In vitro and in vivo studies of 3,4-dihydro-6-{4-[(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), a novel positive inotropic drug, in various animals. Arzneimittelforschung 34, 342-346 (1984)
14 Kitada, Y., Narimatsu, A., Matsumura, N. and Endo, M.: Contractile proteins: possible targets for the cardiotonic action of MCI-154, a novel
cardiotonic agent? Eur. J. Pharmacol. 134, 229–231 (1987)

15 Kitada, Y., Narimatsu, A., Matsumura, N. and Endo, M.: Increase in $\text{Ca}^{++}$ sensitivity of the contractile system by MCI-154, a novel cardiotonic agent, in chemically skinned fibers from the guinea pig papillary muscles. J. Pharmacol. Exp. Ther. 243, 633–638 (1987)

16 Scholz, H.: Inotropic drugs and their mechanisms of action. J. Am. Coll. Cardiol. 4, 389–397 (1984)

17 Siegl, P.K.S.: Overview of cardiac inotropic mechanisms. J. Cardiovasc. Pharmacol. 8, Supp. 9, S1–S10 (1986)

18 Pitts, B.J.R. and Schwartz, A.: Improved purification and partial characterization of (Na+, $\text{K}^+$)-$\text{ATPase}$ from cardiac muscle. Biochim. Biophys. Acta 401, 184–195 (1975)

19 Ohizumi, Y. and Yasumoto, T.: Contractile response of the rabbit aorta to maitotoxin, the most potent marine toxin. J. Physiol. (Lond.) 337, 711–721 (1983)

20 Harigaya, S. and Schwartz, A.: Rate of calcium binding and uptake in normal animal and failing human cardiac muscle. Circ. Res. 25, 781–794 (1969)

21 Nakamura, Y., Kobayashi, J., Gilmore, J., Mascal, M., Rinehart, K.L., Jr., Nakamura, H. and Ohizumi, Y.: Bromo-eudistomin D, a novel inducer of calcium release from fragmented sarcoplasmic reticulum that causes contractions of skinned muscle fibers. J. Biol. Chem. 261, 4139–4142 (1986)

22 Kobayashi, M., Shoji, N. and Ohizumi, Y.: Gingerol, a novel cardiotonic agent, activates the $\text{Ca}^{2+}$-pumping ATPase in skeletal and cardiac sarcoplasmic reticulum. Biochim. Biophys. Acta 903, 96–102 (1987)

23 Honerjäger, P., Heiss, A., Schäfer-Korting, M., Schönsteiner, G. and Reiter, M.: UD-CG 115–a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle. Naunyn Schmiedebergs Arch. Pharmacol. 325, 259–269 (1984)

24 Endo, M. and Kitazawa, T.: E-C coupling studies on skinned cardiac fibers. In Biophysical Aspects of Cardiac Muscle, Edited by Morad, M., p. 307–327, Academic Press, New York and London (1978)

25 Kobayashi, M., Ishida, Y., Shoji, N. and Ohizumi, Y.: Cardiotonic action of [8]-gingerol, an activator of the $\text{Ca}^{2+}$-pumping adenosine triphosphatase of sarcoplasmic reticulum, in guinea pig atrial muscle. J. Pharmacol. Exp. Ther. 246, 667–673 (1988)

26 Grossman, W., McLaurin, L.P. and Rolett, E.L.: Alterations in left ventricular relaxation and diastolic compliance in congestive cardiomyopathy. Cardiovasc. Res. 13, 514–522 (1979)

27 Monrad, E.S., McKay, R.G., Baim, D.S., Colucci, W.S., Fifer, M.A., Heller, G.V., Royal, H.D. and Grossman, W.: Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 70, 1030–1037 (1984)